Jesús
Fortun Abete
Profesor/a Asociado/a en CC. de la Salud
Hospital Universitario Virgen de las Nieves
Granada, EspañaPublikationen in Zusammenarbeit mit Forschern von Hospital Universitario Virgen de las Nieves (10)
2024
-
A Phase III Randomized Controlled Trial of Plitidepsin, a Marine-Derived Compound, in Hospitalized Adults With Moderate COVID-19
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Vol. 79, Núm. 4, pp. 910-919
2023
-
Breakthrough invasive fungal infection among patients with haematologic malignancies: A national, prospective, and multicentre study
Journal of Infection, Vol. 87, Núm. 1, pp. 46-53
2020
-
Executive Summary of the Consensus Document on the Diagnosis and Management of Patients with Primary Immunodeficiencies
Journal of Allergy and Clinical Immunology: In Practice, Vol. 8, Núm. 10, pp. 3342-3347
-
Executive Summary of the Consensus Document on the Diagnosis and Management of Patients with Primary Immunodeficiencies
Enfermedades Infecciosas y Microbiologia Clinica, Vol. 38, Núm. 9, pp. 438-443
2018
-
Analysis of spontaneous resolution of cytomegalovirus replication after transplantation in CMV-seropositive patients with pretransplant CD8+IFNG+ response
Antiviral Research, Vol. 155, pp. 97-105
-
Lack of evidence of association between IFNG and IL28B polymorphisms and QuantiFERON-CMV test results in seropositive transplant patients
Human Immunology, Vol. 79, Núm. 6, pp. 499-505
2017
-
Simplification to dual therapy (atazanavir/ritonavir1lamivudine) versus standard triple therapy [atazanavir/ritonavir1two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study)
Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 1, pp. 246-253
2016
-
Human immunodeficiency virus infection does not worsen prognosis of liver transplantation for hepatocellular carcinoma
Hepatology, Vol. 63, Núm. 2, pp. 488-498
2015
-
Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial
The Lancet Infectious Diseases, Vol. 15, Núm. 7, pp. 775-784
2014
-
EPICO 2.0 project. Development of educational therapeutic recommendations using the DELPHI technique on invasive candidiasis in critically ill adult patients in special situations
Revista Iberoamericana de Micologia, Vol. 31, Núm. 3, pp. 157-175